Page 141 - Read Online

Chan et al. J Transl Genet Genom 2024;8:13-34 https://dx.doi.org/10.20517/jtgg.2023.36 Page 135

2 diabetes receiving integrated care -the genetic testing and patient empowerment (GEM) trial. Diabetes Res Clin Pract
2022;189:109969. DOI
119. Grant RW, Hivert M, Pandiscio JC, Florez JC, Nathan DM, Meigs JB. The clinical application of genetic testing in type 2 diabetes: a
patient and physician survey. Diabetologia 2009;52:2299-305. DOI PubMed PMC
120. Bensellam M, Jonas JC, Laybutt DR. Mechanisms of β-cell dedifferentiation in diabetes: recent findings and future research
directions. J Endocrinol 2018;236:R109-43. DOI PubMed
121. Holman RR. Assessing the potential for α-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998;40 Suppl:S21-5.
DOI PubMed
122. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly
diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753-60. DOI
123. Chan JCN, Paldánius PM, Mathieu C, Stumvoll M, Matthews DR, Del Prato S. Early combination therapy delayed treatment
escalation in newly diagnosed young-onset type 2 diabetes: a subanalysis of the VERIFY study. Diabetes Obes Metab 2021;23:245-
51. DOI PubMed
124. Luk AOY, Lau ESH, Lim C, et al. Diabetes-related complications and mortality in patients with young-onset latent autoimmune
diabetes: a 14-year analysis of the prospective Hong Kong diabetes register. Diabetes Care 2019;42:1042-50. DOI
125. Fan B, Lim CKP, Poon EWM, et al. Differential associations of GAD antibodies (GADA) and C-peptide with insulin initiation,
glycemic responses, and severe hypoglycemia in patients diagnosed with type 2 diabetes. Diabetes Care 2023;46:1282-91. DOI
PubMed PMC
126. Berger B, Stenström G, Sundkvist G. Random C-peptide in the classification of diabetes. Scand J Clin Lab Invest 2000;60:687-93.
DOI PubMed
127. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes.
Diabetologia 2004;46:3-19. DOI
128. Fan B, Wu H, Shi M, et al. Associations of the HOMA2-%B and HOMA2-IR with progression to diabetes and glycaemic
deterioration in young and middle-aged Chinese. Diabetes Metab Res Rev 2022;38:e3525. DOI
129. Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven
cluster analysis of six variables. Lancet Diabetes Endocrinol 2018;6:361-9. DOI
130. Li X, Yang S, Cao C, et al. Validation of the Swedish Diabetes re-grouping scheme in adult-onset diabetes in China. J Clin
Endocrinol Metab 2020;105:e3519-28. DOI
131. Ke C, Narayan KMV, Chan JCN, Jha P, Shah BR. Pathophysiology, phenotypes and management of type 2 diabetes mellitus in
Indian and Chinese populations. Nat Rev Endocrinol 2022;18:413-32. DOI PubMed PMC
132. Chan SP, Lim LL, Chan JCN, Matthews DR. Adjusting the use of glucose-lowering agents in the real-world clinical management of
people with type 2 diabetes: a narrative review. Diabetes Ther 2023;14:823-38. DOI PubMed PMC
133. Shields BM, Dennis JM, Angwin CD, et al; TriMaster Study group. Patient stratification for determining optimal second-line and
third-line therapy for type 2 diabetes: the TriMaster study. Nat Med 2023;29:376-83. DOI PubMed PMC
134. Chow E, Yang A, Chung CHL, Chan JCN. A clinical perspective of the multifaceted mechanism of metformin in diabetes, infections,
cognitive dysfunction, and cancer. Pharmaceuticals 2022;15:442. DOI PubMed PMC
135. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet
2011;378:182-97. DOI PubMed
136. Dennis JM. Precision medicine in type 2 diabetes: using individualized prediction models to optimize selection of treatment. Diabetes
2020;69:2075-85. DOI PubMed PMC
137. Ko GT, So WY, Tong PC, et al. Effect of interactions between C peptide levels and insulin treatment on clinical outcomes among
patients with type 2 diabetes mellitus. CMAJ 2009;180:919-26. DOI PubMed PMC
138. Matthews D, Del Prato S, Mohan V, et al. Insights from VERIFY: early combination therapy provides better glycaemic durability
than a stepwise approach in newly diagnosed type 2 diabetes. Diabetes Ther 2020;11:2465-76. DOI PubMed PMC
139. Diabetes Association Professional Practice Committee. 5. Facilitating behavior change and well-being to improve health outcomes:
standards of medical care in diabetes-2022. Diabetes Care 2022;45:S60-82. DOI PubMed
140. Lao TT, Chan BC, Leung WC, Ho LF, Tse KY. Maternal hepatitis B infection and gestational diabetes mellitus. J Hepatol
2007;47:46-50. DOI PubMed
141. Magee MJ, Khakharia A, Gandhi NR, et al. Increased risk of incident diabetes among individuals with latent tuberculosis infection.
Diabetes Care 2022;45:880-7. DOI PubMed PMC
142. Golden SH, Lazo M, Carnethon M, et al. Examining a bidirectional association between depressive symptoms and diabetes. JAMA
2008;299:2751-9. DOI PubMed PMC
143. Harris ML, Oldmeadow C, Hure A, Luu J, Loxton D, Attia J. Stress increases the risk of type 2 diabetes onset in women: a 12-year
longitudinal study using causal modelling. PLoS One 2017;12:e0172126. DOI PubMed PMC
144. Fisher EB, Chan JC, Nan H, Sartorius N, Oldenburg B. Co-occurrence of diabetes and depression: conceptual considerations for an
emerging global health challenge. J Affect Disord 2012;142 Suppl:S56-66. DOI PubMed
145. Peyrot M, Burns KK, Davies M, et al. Diabetes attitudes wishes and needs 2 (DAWN2): a multinational, multi-stakeholder study of
psychosocial issues in diabetes and person-centred diabetes care. Diabetes Res Clin Pract 2013;99:174-84. DOI
146. Nicolucci A, Kovacs Burns K, Holt RI, et al; DAWN2 Study Group. Diabetes attitudes, wishes and needs second study (DAWN2™):